United Therapeutics Corporation announced the world's first transplant of a UKidney into a living person, which occurred on November 25, 2024. The recipient was a 53-year-old patient with end-stage renal disease who had been unable to find a suitable donor kidney.
This groundbreaking procedure was authorized by the U.S. Food and Drug Administration (FDA) under the expanded access pathway, also known as 'compassionate use.' The UKidney is an investigational xenokidney derived from a pig with 10 gene edits, designed to facilitate immune acceptance and function in a human recipient.
This marks the fourth xenotransplant using United Therapeutics' xeno organs into living humans, following previous UHeart and UThymoKidney transplants. The company plans to submit an Investigational New Drug (IND) application for a UKidney clinical trial shortly, with the goal of initiating a human clinical study in 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.